Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on May 26, 2009
JNCI Journal of the National Cancer Institute 2009 101(11):775-777; doi:10.1093/jnci/djp151
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/11/775    most recent
djp151v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rowan, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rowan, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

NEWS

Intraperitoneal Therapy for Ovarian Cancer: Why Has It Not Become Standard?

Karen Rowan

The first 150 words of the full text of this article appear below.

Three randomized, controlled trials have demonstrated substantial improvements in overall survival for patients with advanced ovarian cancer who received chemotherapy via the intraperitoneal (IP) route—injected directly into the peritoneal cavity—compared with those who received it intravenously. Moreover, the National Cancer Institute has recommended that intraperitoneal treatment to be the standard of care. But according to those who treat ovarian cancer, only about half of the physicians in the field have accepted the technique.

Toxic effects, technical complications with the procedure, and concerns about study designs have all contributed to the lack of acceptance. And, as these phase III trials were under way, the drugs used to treat ovarian cancer evolved: paclitaxel replaced cyclophosphamide; carboplatin replaced cisplatin; and now, new targeted agents such as bevacizumab are being eyed for possible additions to current regimens.

Some physicians point to studies showing that patients may live more than a year longer if given . . . [Full Text of this Article]

Toxicity, Technical Challenges


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?